Breast Cancer

ARUP’s test menu includes ER and PR testing, and various ERBB2 (HER2/neu) testing methods such as HercepTest, INFORM HER2 Dual ISH, PathVision ERBB2 (HER2/neu)FISH and ERBB2 (HER2) Gene Amplification. ARUP offers a sensitive PIK3CA pyrosequencing test that is capable of detecting mutations in all three positions in the three hotspot codons with no pseudogene interference. CellSearch circulating tumor cell counting is also available for assessing patient prognosis.
  • Chief, Division of Anatomic and Molecular Oncologic Pathology
    Dr. Bronner is a Carl R. Kjeldsberg presidential endowed professor of pathology at the University of Utah School of Medicine. Dr. Bronner received her MD from the University of Pennsylvania and completed her pathology residency training and chief residency at the Hospital of the University of Pennsylvania in Philadelphia. Dr. Bronner’s honors include her election as president of the GI Pathology Society, election as council member of the United States and Canadian Academy of Pathology, and, in 2005, the award of the Arthur Purdy Stout Prize, recognizing her work as a surgical pathologist under the age of 45 whose research publications have had a major impact on diagnostic pathology. Dr. Bronner is an editorial journal board member for Human Pathology and Modern Pathology. She has served as an investigator on numerous NIH and foundation grants over the course of her career and has published more than 100 peer-reviewed articles and numerous book chapters.
  • Medical Director, Anatomic Pathology and Cytopathology
    Dr. Factor is an assistant professor of pathology, director of breast pathology, and co-director of the Cytopathology Fellowship Program at the University of Utah School of Medicine. She received her master of health science from Johns Hopkins School of Public Health and her MD from the Albert Einstein College of Medicine in Bronx, New York, followed by residency and fellowships at Brigham and Women’s Hospital in Boston. Dr. Factor is board certified in anatomic pathology and cytopathology, and is a member of the College of American Pathology, the United States and Canadian Academy of Pathology, and the American Society for Clinical Pathology. Her research interests include the biology and prevention of breast cancer.
  • Medical Director, Anatomic Pathology

    Dr. Gligorich is a research assistant professor at the University of Utah School of Medicine. He received his PhD from the University of Utah in organic chemistry and completed a Department of Defense Breast Cancer Research Program postdoctoral fellowship at the Huntsman Cancer Institute. Before joining the University of Utah’s Department of Pathology, Dr. Gligorich was the director of the Molecular Diagnostics Section of the Biorepository and Molecular Pathology Shared Resource at the Huntsman Cancer Institute. His research is focused on the development of ultra-sensitive cell-free tumor DNA tests using next-generation sequencing and digital PCR.

  • Medical Director, Molecular Genetics and Genomics
    Medical Director, Pharmacogenomics
    Dr. Yuan Ji is an Assistant Professor of Pathology at the University of Utah School of Medicine. She received her PhD in Molecular Pharmacology and Experimental Therapeutics at the Mayo Clinic in Rochester, Minnesota, where she further completed her postdoctoral research fellowship in Pharmacogenomics, an NIH-T32 Clinical Pharmacology fellowship and an ABMGG fellowship in Clinical Molecular Genetics. Dr. Ji received multiple early career development awards and grants, including an NIH-KL2 Mentored Career Award and a Minnesota Partnership for Biotechnology and Medical Genomics Award. Dr. Ji is board certified in both Clinical Pharmacology and Medical Genetics and Genomics. Dr. Ji’s major clinical and research focus is in Pharmacogenomics, i.e., identifying novel Pharmacogenomics markers and accurately testing, interpreting, and reporting pharmacogenomic variants. In addition, Dr. Ji also developed a vast interest in developing cost-effective diagnostic testing for diseases including somatic overgrowth and related syndromes.
  • Medical Director, Toxicology
    Medical Director, Pharmacogenetics
    Scientific Director, Mass Spectrometry
    Dr. McMillin is a professor of pathology at the University of Utah School of Medicine. She received her PhD in pharmacology and toxicology from the University of Utah and is certified by the American Board of Clinical Chemistry in clinical chemistry and toxicological chemistry. She is a member of ARUP’s R&D Executive Committee, and is actively involved in professional associations such as the International Association of Therapeutic Drug Monitoring and Clinical Chemistry (IATDMCT), the American Association for Clinical Chemistry (AACC), and the College of American Pathologists (CAP). Her primary interests include detection of neonatal drug exposures, pain management, and clinical applications and implementation of pharmacogenomics.
  • Chief Executive Officer, ARUP Laboratories

    Dr. Perkins is the CEO of ARUP Laboratories and a professor of pathology at the University of Utah School of Medicine. Dr. Perkins has been with ARUP and the University of Utah for over 25 years. During this time, she has served in numerous leadership roles, including director of hematopathology, interim department chair, division chief of clinical pathology, director of the ARUP R&D Institute, and, for the past 10 years, member of the ARUP Laboratories' executive management team. She is a tenured professor at the University of Utah School of Medicine, board certified in anatomic pathology, and holds a special qualification in hematology. She has authored over 200 peer-reviewed journal articles and 70 book chapters in hematopathology. She received her PhD in biochemistry from the University of Miami, and earned her MD and completed her pathology residency at Washington University in St. Louis. She completed her hematopathology fellowship under Dr. Carl Kjeldsberg at the University of Utah.